Bioventus completes acquisition of Israeli firm CartiHeal in deal worth up to $450M
Bioventus has chosen to exercise its option to acquire an Israeli firm, CartiHeal, following the premarket approval of its technology by the U.S. FDA.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
